Only 4.5% of our AS group had pregestational diabetes, which was similar to the findings of the cohort by McElwee, et al, where only 3% of inappropriate AS exposures were in the setting of pregestational diabetes.(10) This is in contrast to the findings of Battarbee, et al, whose survey showed that greater than 50% of the providers reported administering betamethasone in the setting of poorly controlled diabetes or diabetes on insulin.(9). This evidence concerns the gene INS and diabetes mellitus.